BUSINESS

COMMERCIALISATION

A New Pro-Angiogenic Nanomedicine For Wound Healing

Description:

In the UK, chronic wounds represent a significant burden to both patients and the NHS. In fact the conservative cost estimate of treating those with chronic wounds is approximately 3% of the total NHS budget. Treatments are based upon the stimulation of angiogenesis, but these are largely ineffective, with some patients dying from chronic wound infections. Consequently, there is a concerted effort within the industry to develop gene therapy solutions and a desperate need for improved treatments. Here, we aim to deliver a new genetic nanomedicine for the efficacious treatment of chronic and acute wounds, which will consist of nanoparticles designed to knockdown a gene, resulting in the stimulation of angiogenesis, via an alternative pathway, but an extremely well-validated pathway so we are highly confident of success. We will also deliver mesenchymal stem cells (MSC) that will stimulate tissue regeneration at chronic wound sites. Both the nanoparticles (NPs) and MSCs will be delivered using a biodegradable multi-layer biomaterial. This biomaterial will be designed to facilitate the temporal controlled delivery of both the nanomedicine and the MSCs in addition to providing the scaffold for new tissue regeneration. The biomaterial will also maintain a physiologically moist microenvironment that will reduce the incidence of bacterial infection at the chronic wound site. This proposal represents a stratified design approach to produce the biomaterial, with optimal cargo loading, to evaluate the efficacy in vitro and in vivo.

 

 

Patent Information:
For Information, Contact:
Ann Mcconnell
The Queen's University of Belfast
02890 971510
Ann.McConnell@qub.ac.uk
Keywords:
  • Chronic disease treatment
  • Case ID
    14-021
    Search for Technologies